[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334169-105":59,"doc-detail-334169-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","epigenetic-and-oncogenic-inhibitors-cooperatively-drive-differentiation-and-kill-kras-mutant-colorectal-cancers","Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers","","Current treatments for KRAS-mutant colorectal cancers are limited by cellular plasticity and compensatory rewiring. This study describes a combined therapeutic strategy that targets epigenetic and oncogenic signals: inhibition of the histone methyltransferase EZH2 synergizes with multiple RAS-pathway inhibitors to produce dramatic tumor regression in vivo. The agents cooperatively suppress WNT-driven transcription, induce a more differentiated intestinal state via TLE4 and differentiation programs, and trigger apoptosis through upregulation of BMF. Cell death can be averted by activating β-catenin, blocking differentiation, or ablating BMF, highlighting a convergence of EZH2 and RAS on oncogenic WNT signaling, intestinal differentiation, and apoptosis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/epigenetic-and-oncogenic-inhibitors-cooperatively-drive-differentiation-and-kill-kras-mutant-colorectal-cancers/334169/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/epigenetic-and-oncogenic-inhibitors-cooperatively-drive-differentiation-and-kill-kras-mutant-colorectal-cancers/334169.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How do EZH2 inhibitors work together with RAS pathway inhibitors in KRAS-mutant colorectal cancer?","Question",{"text":112,"@type":113},"EZH2 inhibition synergizes with RAS-pathway inhibitors to induce strong tumor regression in vivo. Together they cooperatively suppress WNT-driven transcription and push cancer cells toward a more differentiated state.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What molecular program drives differentiation in the treated colorectal cancers?",{"text":117,"@type":113},"The strategy induces the Groucho/transducin-like enhancer corepressor TLE4, along with a network of WNT pathway inhibitors and intestinal differentiation proteins. This supports a transition into a differentiated cell state.",{"name":119,"@type":110,"acceptedAnswer":120},"Why do the differentiated cells die after treatment, and how can cell death be prevented?",{"text":121,"@type":113},"Treatment induces the proapoptotic protein BMF, which kills the more differentiated cells. Cell death can be prevented by activating β-catenin, blocking differentiation, or ablating BMF expression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334169,1790167160,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":4},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","ReseaRch aRticle   \nEpigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and  \nKill KRAS-Mutant Colorectal Cancers   \nPatrick Loi1,2, Amy E. Schade1,2, Carrie L. Rodriguez1,2, Anjana Krishnan1,2, Naiara Perurena1,2,  \nVan T.M. Nguyen3, Yilin Xu4,5,6,7, Marina Watanabe1,2, Rachel A. Davis1,2, Alycia Gardner1,2,  \nNatalie F. Pilla1,2, Kaia Mattioli1,2, Olesja Popow2,8, Nuray Gunduz9, 10, Tamsin R.M. Lannagan9, 10,  \nSamantha Fitzgerald2,8, 11, Ewa T. Sicinska8, Jia-Ren Lin4,5,6,7, William Tan8, Lauren K. Brais8,  \nKevin M. Haigis2,8, Marios Giannakis2,8, 11, Kimmie Ng8, Sandro Santagata4,5,6,7, Kristian Helin3,  \nOwen J. Sansom9, 10, and Karen Cichowski1,2,4  \nCurrent treatments for KRAS-mutant colorectal cancers are often limited by  \ncellular plasticity and rewiring responses. Here we describe a promising therapeutic strategy that simultaneously targets epigenetic and oncogenic signals. Specifically, we show that inhibitors of histone methyltransferase, EZH2, synergize with various rat sarcoma virus (RAS) pathway inhibitors and promote dramatic tumor regression in vivo. Together these agents cooperatively suppress Wingless and Int-1 (WNT)-driven transcription and drive colorectal cancers into amore differentiated cell state by inducing the Groucho/transducin-like enhancer corepressor, TLE4 , along with a network of WNT pathway inhibitors and intestinal differentiation proteins. However, these agents also induce the proapoptotic protein BCL2 modifying factor (BMF), which subsequently kills these more differentiated cells. Accordingly, cell death can be prevented by activating β-catenin, by blocking differentiation, or by ablating BMF expression. Collectively, these studies reveal a new therapeutic approach for treating KRAS-mutant colorectal cancers and illustrate a critical convergence of EZH2 and RAS on oncogenic WNT signals, intestinal differentiation, and apoptosis.  \nSIgnIfICAnCE: Combined EZH2 and RAS pathway inhibitors kill KRAS-mutant colorectal cancer cells and promote durable tumor regression in vivo. These agents function by cooperatively suppressing the WNT pathway, driving differentiation, and epigenetically reprogramming cells to permit the induction of apoptotic signals, which then kill these more differentiated tumor cells.  \nintRoduction  \nColorectal cancers represent the second highest cause of cancer mortality worldwide, with a 5-year survival rate of \u003C 13% for advanced disease (1–3) . Many colorectal cancers exhibit hyperactivated RAS/RAF/MEK/ERK signaling, with activating KRAS mutations occurring in 40% to 50% of all colorectal cancers (4–7) . Conventional chemotherapies have limited efficacy in advanced tumors, and single-agent kinase inhibitors, including MEK-and EGFR-targeted therapies, are ineffective against colorectal cancers that harbor KRAS mutations (8, 9). Fortunately, the KRASG12C inhibitor, adagrasib, combined with the EGFR-directed antibody, cetuximab, has  \n1Genetics Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts. 2Harvard Medical School, Boston, Massachusetts. 3Division of Cancer Biology, The Institute of Cancer Research, London, United Kingdom. 4Ludwig Center at Harvard, Boston, Massachusetts. 5Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts. 6Department of Systems Biology, Harvard Medical School, Boston, Massachusetts. 7Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts. 8Dana Farber Institute, Boston, Massachusetts. 9CRUK Beatson Institute, Glasgow, United Kingdom. 10School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. 11Broad Institute of MIT and Harvard, Cambridge, Massachusetts.  \nP. Loi and A.E. Schade contributed equally to this article.  \nCorresponding Author: Karen Cichowski, Harvard University, 77 Avenue Louis Pasteur, 458D NRB, Boston, MA 02115. E-mail:  \n[kcichowski@rics. bwh. harvard.edu](kcichowski@rics. bwh. harvard","cbCaifSFN3U58bf4","https://ap.wps.com/l/cbCaifSFN3U58bf4","pdf",9805820,"English","# Introduction\n## EZH2 and epigenetic regulation in solid tumors\n# Abstract/Significance\n## Combined EZH2 and RAS-pathway targeting effects","[{\"question\":\"How do EZH2 inhibitors work together with RAS pathway inhibitors in KRAS-mutant colorectal cancer?\",\"answer\":\"EZH2 inhibition synergizes with RAS-pathway inhibitors to induce strong tumor regression in vivo. Together they cooperatively suppress WNT-driven transcription and push cancer cells toward a more differentiated state.\"},{\"question\":\"What molecular program drives differentiation in the treated colorectal cancers?\",\"answer\":\"The strategy induces the Groucho/transducin-like enhancer corepressor TLE4, along with a network of WNT pathway inhibitors and intestinal differentiation proteins. This supports a transition into a differentiated cell state.\"},{\"question\":\"Why do the differentiated cells die after treatment, and how can cell death be prevented?\",\"answer\":\"Treatment induces the proapoptotic protein BMF, which kills the more differentiated cells. Cell death can be prevented by activating β-catenin, blocking differentiation, or ablating BMF expression.\"}]","Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers | PDF",1790005606]